Niemannbennedsen0932

Lasting programme focus requires clearly defined and articulated priorities and direction. This paper provides a detailed summary of the process that can be used by programme management to ensure that business continuity programmes are implemented and maintained in alignment with the strategic direction of the organisation.The recognition that community resilience is directly tied to the ability of businesses to recover from disaster has spawned a renewed focus on how businesses, especially large corporations, manage the impact of disasters on their employees, facilities and business operations. As the number of worldwide natural and human-caused disasters continues to increase, the need for corporate emergency managers has never been greater. With this influx of demand come new challenges for emergency managers, particularly for those coming from the public sector into corporate settings. This paper draws on the author's experience as an emergency manager at three Fortune 100 companies, and identifies a path forward for emergency management in the corporate world.Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating anti-apoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of B cell receptor (BCR) signaling pathway are two important pathogenic factors for DLBCL. In this study, our aim is to explore a rational combination of BCL-2 inhibitor plus Bruton's tyrosine kinase (BTK) blockade or p53 activation for treating DLBCL with the above characteristics. We demonstrated that a novel BCL-2 selective inhibitor APG-2575 effectively suppressed DLBCL with BCL-2 high expression via activating the mitochondrial apoptosis pathway. BTK inhibitor ibrutinib combined with BCL-2 inhibitors showed synergistic antitumor effect in DLBCL with mean expression of BCL-2 and myeloid cell leukemia-1 (MCL-1) through upregulating the expression level of BIM and modulating MCL-1 and p-Akt expression. For p53 wild-type DLBCL with high expression of BCL-2, APG-2575 showed strong synergic effect with Mouse double minute 2 (MDM2)-P53 inhibitor APG-115 that can achieve potent anti-tumor effect and markedly prolong survival in animal models. Collectively, our data provides an effective and precise therapeutic strategy through rational combination of BCL-2 and BTK or MDM2-P53 inhibitors for DLBCL, which deserves further clinical investigation.BACKGROUND. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) have emerged as important peripheral inflammatory biomarkers. Recent data suggest a possible role of the immune system in the pathophysiology of suicidal behavior (SB). The aim of this study is to evaluate the association among NLR, MLR, and PLR and SB in patients with major depressive disorder (MDD), and to test its validity as a biomarker for suicidality. METHODS. We evaluated 538 patients with MDD (mean age [standard deviation] = 43.87 [14.36] years; females 68.8%). A logistic regression model was estimated to determine the independent factors associated with suicide risk in patients with and without a history of suicide attempt (SA). RESULTS. Three hundred ninety-three patients (74.7%) had a personal history of SA. Patients with a previous SA were more frequently female (71.9% vs. see more 59.6%; p = 0.007), significantly younger (41.20 vs. 51.77 years; p  less then  0.001), had lower depression severity at enrolment (15.58 vs. 18.42; p  less then  0.000), and significantly higher mean NLR and PLR ratios (2.27 vs. 1.68, p = 0.001; 127.90 vs. 109.97, p = 0.007, respectively). In the final logistic regression model, after controlling for age, sex, and depression severity, NLR was significantly associated with SB (β = 0.489, p = 0.000; odds ratio [95% confidence intervals] = 1.631 [1.266-2.102]). We propose a cut-off value of NLR = 1.30 (sensitivity = 75% and specificity = 35%). CONCLUSIONS. Our data suggest that NLR may be a valuable, reproducible, easily accessible, and cost-effective strategy to determine suicide risk in MDD.BACKGROUND. Self-stigma is a major issue in serious mental illness (SMI) and is negatively associated with patient outcomes. Most studies have been conducted in schizophrenia (SZ). Less is known about self-stigma in other SMI and autism spectrum disorder (ASD). The objectives of this study are (i) to assess the frequency of self-stigma in a multicentric nonselected psychiatric rehabilitation SMI and ASD sample; and (ii) to investigate the correlates of elevated self-stigma in different SMI conditions and in ASD. METHODS. A total of 738 SMI or ASD outpatients were recruited from the French National Centers of Reference for Psychiatric Rehabilitation cohort (REHABase). Evaluations included sociodemographic data, illness characteristics, and standardized scales for clinical severity, quality of life, satisfaction with life, wellbeing, personal recovery, a large cognitive battery, and daily functioning assessment. RESULTS. 31.2% of the total sample had elevated self-stigma. The highest prevalence (43.8%) was found in borderline personality disorder and the lowest (22.2%) in ASD. In the multivariate analysis, elevated self-stigma was best predicted by early stages of personal recovery (moratorium, p = 0.001, OR = 4.0 [1.78-8.98]; awareness, p = 0.011, OR = 2.87 [1.28-6.44]), history of suicide attempt (p = 0.001, OR = 2.27 [1.37-3.76]), insight (p = 0.002, OR = 1.22 [1.08-1.38]), wellbeing (p = 0.037, OR = 0.77 [0.60-0.98]), and satisfaction with interpersonal relationships (p  less then  0.001, OR = 0.85 [0.78-0.93]). CONCLUSIONS. The present study has confirmed the importance of addressing self-stigma in SMI and ASD patients enrolled in psychiatric rehabilitation. The effectiveness of psychiatric rehabilitation on self-stigma and the potential mediating effects of changes in self-stigma on treatment outcomes should be further investigated.BACKGROUND. Policies addressing the physical health of people with mental disorders have historically focused on those with severe mental illness (SMI), giving less prominence to the more prevalent common mental disorders (CMDs). Little is known about the comparative physical health outcomes of these patient groups. We aimed to first compare the (a) number of past-year chronic physical conditions and (b) recent physical health service utilization between CMDs vs. SMI, and secondly compare these outcomes between people with CMDs vs. people without mental disorders. METHODS. We analyzed cross-sectional data from the third Adult Psychiatric Morbidity Survey, a representative sample of the English population. We determined the presence of physical conditions and health service utilization by self-report and performed logistic regression models to examine associations of these outcomes between participant groups. RESULTS. Past-year physical conditions were reported by the majority of participants (CMDs, n = 815, 62.